Abstract 6498: MEK inhibitor mirdametinib suppresses MAP kinase pathway activity and inhibits tumor growth in atypical teratoid/rhabdoid tumors
Yiming Deng(Johns Hopkins University), Eric H. Raabe(Johns Hopkins University), Anupa Geethadevi(Bloomberg (United States)), Jeffrey Rubens(Johns Hopkins University), Tyler Findlay(Johns Hopkins University), Kristen Malebranche(Johns Hopkins University), Charles G. Eberhart(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Altered Telomeres in Tumors with <i>ATRX</i> and <i>DAXX</i> Mutations
|Science|2011|1.1k
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711